tiprankstipranks
Advertisement
Advertisement

IMVT Stock Latest News

Immunovant price target raised to $32 from $29 at Goldman Sachs
The FlyImmunovant price target raised to $32 from $29 at Goldman Sachs
9d ago
IMVT
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
PremiumWeekend Updates
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
12d ago
SG
VOR
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
PremiumRatings
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
17d ago
IMVT
Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus
PremiumThe Fly
Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus
21d ago
F
BP
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
PremiumRatings
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
21d ago
IMVT
Immunovant price target lowered to $50 from $52 at Leerink
PremiumThe FlyImmunovant price target lowered to $50 from $52 at Leerink
21d ago
IMVT
Morning Movers: Immunovant sinks after batoclimab trials miss goal
Premium
The Fly
Morning Movers: Immunovant sinks after batoclimab trials miss goal
21d ago
BP
ALK
Video: Globalstar jumps after report of Amazon deal interest
Premium
The Fly
Video: Globalstar jumps after report of Amazon deal interest
21d ago
CVX
DAL
Immunovant reports batoclimab clinical studies missed primary endpoint
PremiumThe Fly
Immunovant reports batoclimab clinical studies missed primary endpoint
22d ago
IMVT
Bernstein initiates Immunovant with a Market Perform, $28 price target
PremiumThe Fly
Bernstein initiates Immunovant with a Market Perform, $28 price target
1M ago
IMVT
Immunovant initiated with a Market Perform at Bernstein
PremiumThe Fly
Immunovant initiated with a Market Perform at Bernstein
1M ago
IMVT
Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity
PremiumRatings
Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity
2M ago
IMVT
Immunovant Rides Brepocitinib Momentum Into 2026
PremiumCompany AnnouncementsImmunovant Rides Brepocitinib Momentum Into 2026
2M ago
IMVT
Immunovant price target raised to $23 from $22 at Truist
Premium
The Fly
Immunovant price target raised to $23 from $22 at Truist
2M ago
IMVT
Immunovant price target raised to $44 from $41 at Guggenheim
Premium
The Fly
Immunovant price target raised to $44 from $41 at Guggenheim
2M ago
IMVT
Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant
PremiumRatings
Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant
3M ago
IMVT
Immunovant reports Q3 EPS (61c), consensus (70c)
PremiumThe Fly
Immunovant reports Q3 EPS (61c), consensus (70c)
3M ago
IMVT
Is IMVT a Buy, Before Earnings?
PremiumPre-Earnings
Is IMVT a Buy, Before Earnings?
3M ago
IMVT
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
PremiumWeekend Updates
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
3M ago
APLS
IMVT
Immunovant price target raised to $22 from $16 at Truist
PremiumThe FlyImmunovant price target raised to $22 from $16 at Truist
4M ago
IMVT
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
Premium
The Fly
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
4M ago
ARGX
IMVT
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
4M ago
IMVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >